中国经济网北京8月21日讯 康希诺(688185.SH)昨日晚间发布2025年半年度报告。今年上半年，公司实现 营业收入3.82亿元，同比增长26.00%；归属于上市公司股东的净利润-1348.54万元，上年同期为-2.25亿 元；归属于上市公司股东的扣除非经常性损益的净利润-8590.09万元，上年同期为-2.55亿元；经营活动 产生的现金流量净额1127.67万元，上年同期为-2.14亿元。 2022年至2024年，康希诺的营业收入分别为10.35亿元、3.57亿元、8.46亿元；归属于上市公司股东的净 利润分别为-9.09亿元、-14.83亿元、-3.79亿元；归属于上市公司股东的扣除非经常性损益的净利润分别 为-10.20亿元、-16.11亿元、-4.41亿元。 康希诺的实际控制人为XUEFENG YU（宇学峰），加拿大国籍；朱涛，中国国籍；、DONGXU QIU （邱东旭），加拿大国籍；HELEN HUIHUA MAO（毛慧华），加拿大国籍。 康希诺募集资金总额为52.01亿元，扣除发行费用后，募集资金净额为49.79亿元。康希诺最终募集资金 净额较原计划多39.79亿元。康希诺2020年8月6日发 ...

万泰生物（603392）公告，全资子公司厦门万泰沧海生物技术有限公司通过《药品生产质量管理规范》 符合性检查。检查范围包括九价人乳头瘤病毒疫苗(大肠埃希菌)的生产车间和生产线，检查时间为2024 年11月5日至11月8日，结论为符合。九价HPV疫苗是公司自主研发的预防用生物制品，覆盖 HPV16/18/31/33/45/52/58七种高危型和HPV6/11两种低危型，可预防上述型别人乳头瘤病毒感染引起的 相关疾病。 ...

Group 1: Financial Performance and Projections - The company aims to strengthen marketing management and expand production capacity to improve operational performance, targeting a significant return for investors [3] - The annual rabies vaccine exposure population in China is approximately 40 million, with a vaccination rate of only 35%, indicating a substantial growth opportunity in the market [3] - The company anticipates a decline in sales for the first quarter of 2025, but expects improvement in the second quarter and the second half of the year [4] Group 2: Product Development and Market Strategy - The company has signed an exclusive licensing agreement with HilleVax, Inc. for the overseas development of a six-valent norovirus vaccine, with clinical trials yet to commence [3] - The company is focusing on the development of a new diploid cell rabies vaccine, which is expected to meet the increasing demand for safer and more effective vaccines [3] - The company plans to enhance its marketing network and brand building to improve product penetration and sales [5] Group 3: Challenges and Responses - The company has faced significant declines in vaccine sales, attributed to industry conditions and competition, but is actively seeking to regain market share [5] - The production expansion project has been delayed, with the company emphasizing the importance of learning from past experiences to avoid future setbacks [4] - The company is committed to improving its operational strategies, including cost control and marketing tactics, to adapt to market changes [7] Group 4: Investor Relations and Market Confidence - The company has repurchased 3 million shares to enhance shareholder value and is focused on restoring investor confidence through improved financial results [6] - The stock price has been under pressure, prompting the company to engage in market management strategies [7] - The management team is experienced and is implementing changes to adapt to competitive pressures and market demands [5]